The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

In the trial, researchers will test how well Medera's SRD-001 gene therapy improves symptoms in heart failure patients with reduced ejection fraction.

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.